Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H10IN3 |
Molecular Weight | 271.091 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1cc(cc(c1)I)CNC(=N)N
InChI
InChIKey=PDWUPXJEEYOOTR-IUAIQHPESA-N
InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)/i9-4
Molecular Formula | C8H10IN3 |
Molecular Weight | 271.091 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
IOBENGUANE I-123 (AdreView®) is a radiopharmaceutical agent for gamma-scintigraphy. It is similar in structure to the antihypertensive drug guanethidine and to the neurotransmitter norepinephrine (NE). IOBENGUANE is, therefore, largely subject to the same uptake and accumulation pathways as NE. It is taken up by the NE transporter in adrenergic nerve terminals and stored in the presynaptic storage vesicles. IOBENGUANE accumulates in adrenergically innervated tissues such as the adrenal medulla, salivary glands, heart, liver, spleen, and lungs as well as tumors derived from the neural crest. By labeling IOBENGUANE with the isotope iodine 123 (I-123), it is possible to obtain scintigraphic images of the organs and tissues in which the radiopharmaceutical accumulates. IOBENGUANE I-123 (AdreView®) is indicated for use in the detection of primary or metastatic pheochromocytoma or neuroblastoma. It is also used for scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart to mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) class II or class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35%. Among these patients, IOBENGUANE I-123 (AdreView®) may be used to help identify patients with lower one and two-year mortality risks, as indicated by an H/M ratio ≥ 1.6.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | ADREVIEW Approved UseAdreView is a radiopharmaceutical agent for gamma-scintigraphy indicated for:
- use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests;
- scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart to mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) class II or class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35%. Among these patients, AdreView may be used to help identify patients with lower one and two year mortality risks, as indicated by an H/M ratio ≥ 1.6. Launch Date1.22169603E12 |
|||
Diagnostic | ADREVIEW Approved UseAdreView is a radiopharmaceutical agent for gamma-scintigraphy indicated for:
- use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests;
- scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart to mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) class II or class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35%. Among these patients, AdreView may be used to help identify patients with lower one and two year mortality risks, as indicated by an H/M ratio ≥ 1.6. Launch Date1.22169603E12 |
|||
Diagnostic | ADREVIEW Approved UseAdreView is a radiopharmaceutical agent for gamma-scintigraphy indicated for:
- use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests;
- scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart to mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) class II or class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35%. Among these patients, AdreView may be used to help identify patients with lower one and two year mortality risks, as indicated by an H/M ratio ≥ 1.6. Launch Date1.22169603E12 |
|||
Diagnostic | ADREVIEW Approved UseAdreView is a radiopharmaceutical agent for gamma-scintigraphy indicated for:
- use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests;
- scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart to mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) class II or class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35%. Among these patients, AdreView may be used to help identify patients with lower one and two year mortality risks, as indicated by an H/M ratio ≥ 1.6. Launch Date1.22169603E12 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 06:01:28 UTC 2021
by
admin
on
Sat Jun 26 06:01:28 UTC 2021
|
Record UNII |
P2TH1XYZ84
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QV09IX01
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
||
|
NCI_THESAURUS |
C2124
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
||
|
FDA ORPHAN DRUG |
226506
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
||
|
WHO-ATC |
V09IX01
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
||
|
FDA ORPHAN DRUG |
226406
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C80094
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
PRIMARY | |||
|
1448
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
PRIMARY | |||
|
SUB12077MIG
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
PRIMARY | |||
|
P2TH1XYZ84
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
PRIMARY | |||
|
CHEMBL818
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
PRIMARY | |||
|
DBSALT002469
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
PRIMARY | |||
|
Iobenguane I 123
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
PRIMARY | |||
|
1426748
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
PRIMARY | RxNorm | ||
|
SUB127296
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
PRIMARY | |||
|
76924-93-1
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
PRIMARY | |||
|
135326
Created by
admin on Sat Jun 26 06:01:28 UTC 2021 , Edited by admin on Sat Jun 26 06:01:28 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |